Moderna (MRNA) Current Assets (2017 - 2026)

Moderna (MRNA) has 10 years of Current Assets data on file, last reported at $5.8 billion in Q1 2026.

• On a quarterly basis, Current Assets fell 14.72% year-over-year to $5.8 billion in Q1 2026; TTM through Mar 2026 was $5.8 billion, a 14.72% decrease from a year earlier, with the FY2025 full-year figure at $6.5 billion, down 19.2% from the prior year.
• Current Assets for Q1 2026 stood at $5.8 billion, down from $6.5 billion in the prior quarter.
• Over the last five years, Current Assets for MRNA reached as high as $16.4 billion in Q1 2022 and fell as low as $5.8 billion in Q1 2026.
• Historically, Current Assets has averaged $10.0 billion across 5 years, with a median of $9.7 billion in 2024.
• Across the five-year window, Current Assets surged 39.71% in 2022 and sank 36.12% in 2025, its largest moves.
• Year by year, Current Assets stood at $13.4 billion in 2022, then slipped by 23.13% to $10.3 billion in 2023, then dropped by 21.56% to $8.1 billion in 2024, then retreated by 19.2% to $6.5 billion in 2025, then declined by 11.83% to $5.8 billion in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $5.8 billion in Q1 2026, $6.5 billion in Q4 2025, and $6.6 billion in Q3 2025.